Description
Product Specifications
| Attribute | Details |
|---|---|
| Product Name | Sildenafil Citrate Orodispersible Tablet (Huiren® / Likexin) |
| Generic Name | Sildenafil Citrate |
| CAS Number | 171599-83-0 |
| Molecular Formula | C22 H3o N604S. CH807 (or C28 H38 N6011S) |
| Molecular Weight | 666.70 g/mol |
| Dosage Form | Orodispersible tablet (ODT) |
| Strength | 50mg per tablet |
| Pack Size | 1 tablet per box |
| Approval Number | China NMPA H20244673 |
| Product Code | 86910323000369 |
| Manufacturer | Jiangxi Huiren Pharmaceutical Co., Ltd. |
| Barcode | 6937999607160 |
| Storage | Store at 15–25°C; protect from light and moisture |
| Intended Use | Laboratory research only |
Mechanism of Action
Sildenafil selectively inhibits PDE5, preventing breakdown of cGMP in smooth muscle cells, leading to enhanced nitric oxide (NO)-mediated vasodilation, especially in penile and pulmonary vasculature.
Research Applications & Pharmacology
Erectile Dysfunction (ED) Models: Widely used to assess cGMP-mediated signaling and vascular responses .
Pulmonary Arterial Hypertension: Employed to investigate PDE5’s role in pulmonary vascular dilation.
Pharmacokinetics of ODTs: Orodispersible formulations dissolve rapidly in seconds—promoting fast absorption without water .
Clinical Parameters: Typical onset ~20 minutes, duration ~2 hours; metabolic clearance by CYP3A4/5; excreted primarily in feces and urine .
Safety Profile & Handling
Common Adverse Effects: Headache, flushing, nasal congestion, dyspepsia, and mild dizziness .
Drug Interactions: Avoid concurrent administration with nitrates or NO donors due to risk of severe hypotension .
Contraindications: Not suitable for models involving cardiovascular compromise or concurrent PDE5-inhibiting agents.
Handling Instructions: Store under recommended conditions, use protective PPE, discard as per institutional safety protocols. This product is strictly for research and not for administration.


Reviews
There are no reviews yet.